NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today an agreement with Self-screen BV to implement a CE-IVD marked molecular diagnostic test for high-risk strains of human papillomavirus (HPV) on the NeuMoDx™ 288 and NeuMoDx™ 96 Molecular Systems. HPV is the virus regarded as the major cause of cervical cancer.
